



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,284	04/21/2005	Eric Fredericus Bernardus Josephus Mar Thunnissen	13634PCTUS	1854
24392	7590	10/17/2008		
FISH & ASSOCIATES, PC			EXAMINER	
ROBERT D. FISH			WOOLWINE, SAMUEL C	
2603 Main Street				
Suite 1050			ART UNIT	
Irvine, CA 92614-6232			PAPER NUMBER	
			1637	
			MAIL DATE	
			DELIVERY MODE	
			10/17/2008	
			PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/511,284

Applicant(s)

THUNNISSEN ET AL.

Examiner

SAMUEL WOOLWINE

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 June 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4 and 10-17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 14, 16 and 17 is/are allowed.
- 6) ☒ Claim(s) 1, 3, 10, 11 and 15 is/are rejected.
- 7) ☒ Claim(s) 2, 4, 12 and 13 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB08)
- Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Status

Applicant's response submitted 09/17/2007 is acknowledged. Claims 1-4 and new claims 10-17 are pending and under consideration.

The objection to the claims made in OA 03/22/2007 is withdrawn in view of Applicant's amendments.

The rejection under 35 U.S.C. 112, 2nd paragraph, made in OA 03/22/2007 is withdrawn in view of Applicant's amendments.

The rejections under 35 U.S.C. 102(b) and 103(a) made in OA 03/22/2007 are withdrawn in view of Applicant's amendments to recite specific SEQ ID NOS.

New grounds of rejection are set forth below.

It is noted that claims 2 and 4 recite "optional" limitations. Such limitations carry no patentable weight since they are not required by the claim, and will not be further addressed.

Priority

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Europe on April 16, 2002. It is noted, however, that applicant has not filed a certified copy of the 02076494.0 application as required by 35 U.S.C. 119(b).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 10, 11 and 15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is vague and indefinite which HPV types are low-risk, high-risk, or "remaining". There is no explicit definition as to what strains fall into what category. While page 1 of the specification as filed indicates, for example, types 16, 18, 45, 31 and 33 are "high-risk", this does not allow one to determine the metes and bounds of the claims. For instance, page 1, lines 26-27 of the specification states: "The number of HR-HPV [high-risk HPV] has been expanded in the last years to e.g. 16, 18 45, 31, 33 check." Hence, the scope of what constitutes a particular risk type is fluid, not definite. It is unclear what Applicant meant by the word "check".

Furthermore, page 6, lines 11-14 of the specification as filed read as follows: "The terms low and high risk HPV denote a difference in association with the chance of development of malignancy. This has especially for the uterine cervix been described. For high risk is the chance of development of malignancy is higher than for the low risk HPV types." Hence, not only is the scope of what constitutes a particular risk type fluid, it is also subjective and relative.

For purposes of examination over the prior art, *any* HPV types will be considered to qualify as high-risk, low-risk or "remaining" types, with the exception that 16, 18, 45, 31 and 33 will be considered high-risk.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3, 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Manos et al (USPN 5,182,377) in view of:

GenBank GI:397060 [online] August 22, 1993 [retrieved on 09/23/2008]

<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?397060:OLDID:456557>

GenBank GI:60955 [online] July 6, 1989 [retrieved on 09/23/2008]

<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?60955:OLDID:34726>

GenBank GI:940299 [online] August 8, 1995 [retrieved on 09/23/2008]

<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=940299>

GenBank GI:6002612 [online] October 1, 1999 [retrieved on 09/23/2008]

<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?6002612:OLD08:69388>
GenBank GI:4103240 [online] January 5, 1999 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=4103240>
GenBank GI:333026 [online] June 2, 1994 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=333026>
GenBank GI:1020266 [online] October 17, 1995 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=1020266>
GenBank GI:1020242 [online] October 17, 1995 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=1020242>
GenBank GI:60295 [online] January 7, 1993 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?60295:OLDID:34483>
GenBank GI:396981 [online] August 22, 1993 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?396981:OLDID:456547>
GenBank GI:333211 [online] February 23, 1994 [retrieved on 09/23/2008]
<http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?396981:OLDID:456547>

With regard to claim 1, Manos teaches *a method of detecting the presence of HPV in a sample comprising:*

amplifying and labeling part of the E1 HPV gene, wherein amplification is performed a primer pair...to thereby form a labeled fragment (column 14, line 38 through column 15, line 30; column 5, lines 40-45; column 8, line 34 through column 9, line 1; column 3, lines 16-20);

hybridizing the labeled fragment to a solid support upon which a plurality of HPV E1 gene-specific capture probes are immobilized (column 14, line 38 through column 15, line 30; column 5, lines 40-45; column 8, line 34 through column 9, line 1; column 1, lines 46-49);

removing uncaptured labeled fragments (see for example column 7, lines 17-19; column 19, lines 1-3; washing would remove uncaptured labeled fragments);

detecting the captured labeled fragment, wherein detection of the fragment indicates presence of HPV in the sample (see for example column 8, lines 35-40; "determine whether a probe has hybridized to a DNA sequence").

With regard to claim 3, Manos teaches using E1 primers in conjunction with E6/7 primers (see column 15, lines 15-20).

With regard to claim 10, Manos teaches using E1 primers in conjunction with E6/7 primers (see column 15, lines 15-20). This would have necessarily required at least four oligonucleotides (primers), since each amplicon would require two primers (column 3, lines 16-20). Manos teaches typing for types 16, 18 and 33 (high-risk types) and 6 and 11 (which can be considered either low-risk or "remaining" types; see column 1, lines 30-40 and Table 9). Furthermore, Manos expressly teaches it is important to identify and type HPV (column 1, line 38-40).

With regard to claim 11, Manos teaches using E1 primers in conjunction with E6/7 primers (see column 15, lines 15-20). This would have necessarily required at least four oligonucleotides (primers), since each amplicon would require two primers

(column 3, lines 16-20). Furthermore, Manos teaches typing for types 16, 18 and 33 (high-risk types).

Manos teaches the concept of using degenerate primers designed based on regions of known homology such that multiple HPV types are amplified (column 3, lines 32-36; column 5, lines 50-53), followed by identification of the specific type by hybridizing the amplified products to type-specific oligonucleotides (column 5, lines 53-57). This appears to be the basis for Applicant's method as well.

Manos does not teach the specific primer and probe sequences (SEQ ID NOs) recited in claim 1.

The primers recited in claim 1 are degenerate primers based on the HPV E1 gene region. The difference between the claimed invention and the prior art disclosed in Manos is simply in the choice of a particular region of the E1 gene and the choice of primers. Therefore the question to be asked is, were there known HPV sequences that, upon comparison with one another, would have suggested these degenerate primers?

Based on Applicant's specification (paragraphs [0040]-[0041] of the published application), it would appear that Applicant selected the recited primers and probes based on known HPV sequences.

SEQ ID NO:1 is GTGCCAGGAWCAGTTGTTAG, whereas SEQ ID NO:4 is TCYTGAAHGTCCAHHGGYTC. In the case of SEQ ID NO:1, "W" represents either "A" or "T", whereas in the case of SEQ ID NO:4, "Y" represents either "T" or "C", and "H" represents "A", "T" or "C" (see Manos, column 4 for a description of base nomenclature). An alignment of portions of GenBank GI sequences 397060, 60955,

Art Unit: 1637

940299, 6002612, 4103240, 333026, 1020266, 1020242, 60295, 396981 and 333211, which were all known at the time the invention was made, indicates conserved nucleotides (*). The region corresponding to SEQ ID NO:1 is indicated with solid underline, whereas the region corresponding to SEQ ID NO:4 is indicated with a dashed underline. As can be seen, these regions were highly conserved, and the differences within these regions accounts for the degenerate bases in SEQ ID NOS:1 and 4. Note that the dashed underline corresponds to the *reverse complement sequence* for SEQ ID NO:4, as that primer corresponds to the complementary strand and would be oriented in the opposite direction to SEQ ID NO:1. Therefore, the degenerate bases are indicated in lower case, e.g. h refers to a base complementary to A, T, or C (i.e. T, A, or G, respectively). Similarly, y refers to a base complementary to T or C (i.e. A or G, respectively). Hence, with regard to claim 1, known HPV sequences would have suggested at least the primer combination SEQ ID NO:1 and 4, since these are found in highly conserved regions.

```

gi|397060|emb|X74463.1|      GAGG-----ATGGAGAAACTATGCCAGGCGCGCTAGATTTTGTGCCAGGAAC 2789
gi|60955|emb|X00203.1|      GAGGAAG---ATGGAAGCAATAGCCAAAGCGTTTAGATGCGTGCCAGGAAC 2762
gi|940299|gb|L41216.1|PPHE6E GAGGAAG---ATGGAAGCAATAGCCAAAGCGTTTAGATGCGTGCCAGGAAC 2763
gi|6002612|gb|AF092932.1|AF092 GAGGAAG---ATGGAAGCAATAGCCAAAGCGTTTAGATGCGTGCCAGGAAC 2763
gi|4103240|gb|AF022227.1|AF022 -----ATGGAAGCAATAGCCAAAGCGTTTAGATGCGTGCCAGGAAC 40
gi|333026|gb|U14119.1|PPH11 GAGGAAG---ATGGAAGCAATAGCCAAAGCGTTTAGATGCGTGCCAGGATC 2762
gi|1020266|gb|U31791.1|HPU3179 GAGGACG---ATGGAGACAATAGCCAAAGCATTTAGATGCTGTGCCAGGAAC 2744
gi|1020242|gb|U31788.1|HPU3178 GAGGACG---ATGGAGACAATAGCCAAAGCATTTAGATGCTGTGCCAGGAAC 2744
gi|60295|emb|X62843.1|      GAGGACG---ATGGAGACAATAGCCAAAGCATTTAGATGCTGTGCCAGGAAC 2764
gi|396981|emb|X74475.1|      GAGGAAGAAATGGAGACACTGGCCAAACGTTTAGATGCGTGCCAGGAAC 2759
gi|333211|gb|X73236.1|PPHPAPV4 GAGGAAGACATATGGAGAGACTGGCCAAACGTTTAGATGCGTGCCAGGAAC 2741
          *****

```

```

gi|397060|emb|X74463.1|      AGTTGTTAGAACTTTATGAACAAAGACAGCAACAGCTACAGCAACCATATA 2839
gi|60955|emb|X00203.1|      AGTTGTTAGAACTTTATGAAGAAACAGTACTGACCTACACAAACATGTA 2812
gi|940299|gb|L41216.1|PPHE6E AGTTGTTAGAACTTTATGAAGAAACAGTACTGACCTACACAAACATGTA 2813
gi|6002612|gb|AF092932.1|AF092 AGTTGTTAGAACTTTATGAAGAAACAGTACTGACCTACACAAACATGTA 2813
gi|4103240|gb|AF022227.1|AF022 AGTTGTTAGAACTTTATGAAGAAACAGTACTGACCTACACAAACATGTA 90
gi|333026|gb|U14119.1|PPH11 AGTTGTTAGAACTTTATGAAGAAACAGTATTGATATACACAAACACATT 2812
gi|1020266|gb|U31791.1|HPU3179 ACTGCTTGAACCTGTATGAAGAAATAGTAATAACCTTACAAAAATATA 2794
gi|1020242|gb|U31788.1|HPU3178 AGTTGTTAGAACTGTATGAAGAAATAGTAATAACCTTACAAAAATATA 2794
gi|60295|emb|X62843.1|      AGTTGTTAGAACTGTATGAAGAAATAGTAATAACCTTACAAAAATATA 2814
gi|396981|emb|X74475.1|      AGTTGTTAGAACTGTATGAGGAAGATAGTAGGGATTTCAGAAAACATATT 2791
gi|333211|gb|X73236.1|PPHPAPV4
          *****

```

Art Unit: 1637

```

gi|397060|emb|X74463.1|      TTGCACCTGGAAATATATACGTTTATGAAAGTGTAATATATTATACAGCAAG 2889
gi|60955|emb|X00203.1|      TTGCATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2862
gi|940299|gb|L41216.1|PPHE6E TTGCATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2863
gi|6002612|gb|AF092932.1|AF092 CTGCATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2865
gi|4103240|gb|AF022227.1|AF022 CTGCATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 140
gi|333026|gb|M14119.1|PPH11 ATGCATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2862
gi|1020266|gb|U31791.1|HPU3179 CAACATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2844
gi|1020242|gb|U31788.1|HPU3178 CAACATTGGAAATGCAATGAGACATGAAAGTGTTATTATATATAAAGCAAA 2844
gi|60295|emb|X62843.1|      CAAACATTGGAAATGCTTTAAGGTACGAAAGTGACTCTTAACACAAAGCAAG 2864
gi|396981|emb|X74475.1|      CAGCAGCTGGAAATGTTTACGCTATGAAAGCAGCGCTTATTATTAAAGGCTCG 2859
gi|333211|gb|M73236.1|PPHPAPV4 GAACATTGGAAATGTTTACGCTATGGAGCCAGCTGATTGTATGAAGGCCCG 2841
      * * * * *
ACAAATGGGCATTAAACGCTTGGGCCACACAGGTGGTGGCAAGTTTAGATG 2939
ACAAATGGGCCTAAAGCCACATAGGAATGCAAGTAGTGCCACGATTAAAGG 2912
ACAAATGGGCCTAAAGCCACATAGGAATGCAAGTAGTGCCACGATTAAAGG 2913
ACAAATGGGCCTAAAGCCACATAGGAATGCAAGTAGTGCCACGATTAAAGG 2913
ACAAATGGGCCTAAAGCCACATAGGAATGCAAGTAGTGCCACGATTAAAGG 190
ACAAATGGGCCTAGCCACATCGGGTTACAAAGTAGTACACCAATTAACG 2912
GCAAAATGGGCCTAAAGCCACATGGGAATGCAAGTAGTGCCACGATTAAAG 2894
GCAAAATGGGCCTAGCCACATGGGAATGCAAGTAGTGCCACGATTAGAC 2914
GCAAAATGGGCCTAGCCACATGGGAATGCAAGTAGTGCCACGATTAGAC 2914
TGAAATGGGCCTATGCAAAATAGGACATCAATAGTGCCGACGACTGGAAA 2909
TGAAATGGGCCTTGCAAAATATAGGACATCAATAGTACCACAAATTGGAAA 2891
      * * * * *
TGTCAAAAGCCAAAGGCCATGCAAGCAATTGAAATGCAAAATGTCTGTAGAA 2989
TGTCGGAAGCAAAAGGACATAATGCAATGCAAAATGCAAAATGCAATTAGAA 2963
TGTCGGAAGCAAAAGGACATAATGCAATGCAAAATGCAAAATGCAATTAGAA 2963
TGTCGGAAGCAAAAGGACATAATGCAATGCAAAATGCAAAATGCAATTAGAA 240
TGTCGAGAGACTAAAGGACATAATGCAATGCAAAATGCAAAATGCAATTAGAA 2962
TGTCACAGACAAAGGGACACACAGGCCAATTGAAATGCAAAATGCAATTAGAA 2944
TGTCACAGACAAAGGGACACACAGGCCAATTGAAATGCAAAATGCAATTAGAA 2944
TATCACAAGCTTAAGGACCAATGAGGCAATTGAAATGCAAAATGCAATTAGAA 2964
TATCACAAGCTTAAGGACCAATGAGGCAATTGAAATGCAAAATGCAATTAGAA 2959
CATGTAGAGTCAAGGCCACATGCAATGAAATACACTGGCATTAGAG 2941
      * * * * *
TCCTTGCAACTACTGAATATAACTTTAGAGCCATTGGAGCTTACAGGACAC 3039
TCATTATTAAAGGACTGAGTATAGTATGGAACTGTGGACATTACAAAGAAAC 3012
TCATTATTAAAGGACTGAGTATAGTATGGAACTGTGGACATTACAAAGAAAC 3013
TCATTATTAAAGGACTGAGTATAGTATGGAACTGTGGACATTACAAAGAAAC 3013
TCATTATTAAAGGACTGAGTATAGTATGGAACTGTGGACATTACAAAGAAAC 290
TCCTTAGCAAAAACCTCAGTATGGTGTGGAACTGTGGACATTACAGGACAC 3012
ACACTATTAAACTCTGACTATGGTATGGAACTGTGGACATTACAGGACAC 2994
ACATTACTAAACTCTGACTATGGTATGGAACTGTGGACATTACAGGACAC 2994
ACATTACTAGAGTCTGAGTTGGTATGGAACTGTGGACATTACAGGACAC 3014
ACATTATTGCAAGTCCCAATTTGGTATGGAACTGTGGACATTACAGGACAC 3009
ACATTATTGCAAGTCTGCTGTTGGTATGGAACTGTGGACATTACAGGACAC 2991
      * * * * *

```

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to modify the methods and kits of Manos in accordance with known HPV sequences such as the recited GenBank GI numbers to arrive at a primer pair of SEQ ID NO:1 and 4 (thus meeting the limitations of claim 1)

since the known sequences indicate these are regions highly conserved among a number of HPV types. Note that Manos taught the concept of using degenerate primers based on regions of known homology to amplify multiple HPV types (column 3, lines 32-36; column 5, lines 50-53), followed by identification of the specific type by hybridizing the amplified products to type-specific oligonucleotides (column 5, lines 53-57). One of ordinary skill in the art would have recognized the difference between the claimed invention and the methods/kits of Manos as simply choosing obvious alternative conserved and regions in which to design the primers.

Conclusion

Claims 2, 4, 12 and 13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 14, 16 and 17 are allowed. These claims require the use of probes selected from the group consisting of SEQ ID NO:24-59. Each of these probes has an identical spacer sequence at the 5' end: TTTTCTTTTCTTTC. There is not teaching or suggestion of this particular spacer sequence in the prior art.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Art Unit: 1637

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached on Mon-Fri 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samuel Woolwine/
Examiner, Art Unit 1637

/GARY BENZION/
Supervisory Patent Examiner, Art Unit 1637